In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) reported that OrbiMed Advisors has picked up 2,524,000 of common stock as of 2017-02-13.

The acquisition brings the aggregate amount owned by OrbiMed Advisors to a total of 2,524,000 representing a 1.73% stake in the company.

For those not familiar with the company, Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. It operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. It is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD). Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD. It has two sGC development candidates, which include IW-1973 and IW-1701.

A glance at Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD)’s key stats reveals a current market capitalization of 2.41 billion based on 130.86 million shares outstanding and a price at last close of $16.42 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2011-11-02, Hecht picked up 50,000 at a purchase price of $11.65. This brings their total holding to 72,803 as of the date of the filing.

On the sell side, the most recent transaction saw Hecht unload 32,994 shares at a sale price of $15.50. This brings their total holding to 4,670,322.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.